Outcomes following KRASG12C inhibitor treatment in patients with KRASG12C-mutated solid tumors: A systematic review and meta-analysis

Objective: To assess the efficacy and safety of FDA-approved KRASG12C inhibitors in patients with KRASG12C-mutated solid tumors. Methods: We searched PubMed, EMBASE, Cochrane Library, and major international conferences for clinical trials published in English up to March 6, 2023. Clinical trials in...

Full description

Bibliographic Details
Main Authors: Qi-An Chen, Wei-Hao Lin, Xiao-Xiang Zhou, Zheng Cao, Xiao-Li Feng, Yi-Bo Gao, Jie He
Format: Article
Language:English
Published: Elsevier 2024-02-01
Series:Pharmacological Research
Subjects:
Online Access:http://www.sciencedirect.com/science/article/pii/S1043661824000045